Uncovering the anti-cancer mechanisms of Immuno-Oncology

The unique mechanism of action of GNTbm-TKI

1. Monotherapy

GNTbm-TKI is a structurally novel multi-kinase inhibitor that selectively targets key signaling pathways, including TYRO3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2. It uniquely integrates dual mechanisms of action, combining direct tumor inhibition with potent immunomodulatory activity.

Beyond directly suppressing tumor cell proliferation, GNTbm-TKI effectively inhibits tumor invasion and metastasis, suppresses tumor angiogenesis, and concurrently modulates immune responses, thereby enhancing overall anti-tumor efficacy.

Importantly, GNTbm-TKI has demonstrated therapeutic potential as a monotherapy, particularly in neuroendocrine tumors (NETs), offering a differentiated treatment option with a novel mechanism of action.

2. Combination therapy

GNTbm-TKI, through its unique activities of both immune activation and multi-target kinase inhibition, can be combined with GNTbm-38 to remodel the TME, attracting CTL infiltration into the TME for selectively attacking tumors, and preventing Immunosuppressive cells from being attracted to the TME. This potent tumor immune toxic can generate lasting immune memory, benefiting long-lasting non-recurrence in anti-cancer effects. On the other hand, combination of GNTbm-TKI plus GNTbm-38 with a anti-PD-1/VEGF bispecific antibody will provide excellent cancer immune treatment benefits, transforming 'cold tumors' into 'hot tumors.' This synergistic effect of multiple different drug mechanisms not only greatly remodels the TME but also activates CTLs for persistent attacks on tumors, significantly enhancing the effectiveness of cancer immunotherapy, broadening the treatment options for various solid tumors classified as cold tumors.

Drug combinations of GNTbm-TKI can be divided into: 

ICI-free: GNTbm-TKI + GNTbm-38 
ICI-based: GNTbm-TKI + GNTbm-38 + anti-PD-1/VEGF bispecific antibody or GNTbm-TKI + anti-PD-1/VEGF bispecific antibody 

The potent remodeling mechanisms of GNTbm-TKI combined with GNTbm-38 in tumor microenvironment 

The mechanisms of tumor immunotherapy of GNTbm-TKI in combination with anti-PD-1/VEGF bispecific antibody